Document is current

Article History

Received: 30 May 2020

Accepted: 16 July 2020

First Online: 24 July 2020

Compliance with ethical standards

:

: Yosuke Kito has received honoraria for lecturing from Chugai Pharmaceutical. Hironaga Satake has received research funding from Ono Pharmaceutical, Taiho Pharmaceutical, and Takeda Pharmaceutical, and honoraria from Bayer, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Merck Biopharma, MSD, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Sanofi, and Yakult Honsha. Hiroya Taniguchi has received research funding from MSD, Daiichi Sankyo, Takeda Pharmaceutical, Dainippon Sumitomo Pharma, Array BioPharma, Sysmex, Ono Pharmaceutical, and Novartis, and honoraria from Sanofi, MSD, Mitsubishi Tanabe Pharma, Nippon Kayaku, Taiho Pharmaceutical, Takeda Pharmaceutical, Yakult Honsha, Bayer, Merck Serono, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, MBL, Novartis, and Chugai Pharmaceutical. Takeshi Yamada has received honoraria from Ono Pharmaceutical, Eli Lilly, and Yakult Honsha. Taito Esaki has received research funding from MSD, Novartis, Dainippon Sumitomo, Ono Pharmaceutical, Daiichi Sankyo, Astellas, Amgen Astellas Biopharma, BeiGene, Pierre Fabre Medicament, Ignyta, Array BioPharma, Bayer, Taiho Pharmaceutical, and Eli Lilly and honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical, MSD, Eli Lilly, Daiichi Sankyo, Nihon Kayaku, Sanofi, Ono Pharmaceutical, Takeda Pharmaceutical, Bayer, Merck Serono, Bristol, and Eisai. Tadamichi Denda has received research funding from MSD and ONO Pharmaceutical, and honoraria from SAWAI Pharmaceutical and Sysmex. Hisateru Yasui has received research funding from MSD, Daiichi Sankyo, and Ono Pharmaceutical, and honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Bristol-Myers Squibb, Daiichi Sankyo, TERUMO, Eli Lilly, Merk Biopharma, and Yakult Honsha. Naoki Izawa has received honoraria from Takeda Pharmaceutical, Eli Lilly, Ono Pharmaceutical, and Daiichi Sankyo. Toshiki Masuishi has received research funding from MSD, Daiichi Sankyo, and Ono Pharmaceutical and honoraria from Takeda, Chugai, Merck Serono, Taiho, Bayer, Lilly Japan, Yakult Honsha, and Sanofi. Toshikazu Moriwaki has received research funding from Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, MSD, and Yakult Honsha and honoraria from Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Sanofi, Ono Pharmaceutical, Eli Lilly, and Yakult Honsha. K. Yamazaki has received honoraria from Bayer, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Merck Serono, Taiho Pharmaceutical, Takeda Pharmaceutical, Yakult Honsha, Sanofi, Ono Pharmaceutical, and Bristol-Myers Squibb. The remaining authors have declared no conflicts of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Patients were informed of the investigational nature of the study and provided their written informed consent before registration.

: Patients signed informed consent regarding publishing their data.

: Kaplan–Meier curve analysis was performed using EZR (Bone Marrow Transplantation 2013: 48, 452–458).